Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Heart failure hope? kidney nerve procedure tested in tiny study

NCT ID NCT04947670

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a procedure called renal denervation, which uses a catheter to calm overactive nerves in the kidneys, in people with chronic heart failure. The goal was to see if it is safe and feasible, and whether it could improve symptoms like walking distance and heart strain. Only 4 patients were enrolled before the study was terminated, so the results are very preliminary.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
renal denervation procedure
What this could lead to
If successful, this could point toward a new way to manage chronic heart failure by calming overactive nerves to the kidneys.
What could go wrong
This was a very small feasibility study (only 4 participants) that was terminated early, so results are limited. The procedure carries risks like any invasive vascular intervention.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

4 people

The number who actually took part.

Started

Jun 2022

Finished

Sep 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient with CHF diagnosed for at least 3 months prior to consent * 6-min walk distance ≤350 m * NYHA Class II-III symptoms of CHF * Systolic left ventricular dysfunction as assessed by echocardiogram with left ventricular ejection fraction \<45% * eGFR calculated (CKD-EPI) \>30 ml/min/1.73 m2 * NT-pro-BNP \>450 pg/ml, \>900 pg/ml for patients with atrial fibrillation * Optimal medical drug therapy according to current guidelines for CHF management. This medication may include loop diuretics, ACEi/ARBs, ARNI, SGLT-2 inhibitors, aldosterone antagonists, and beta-blockers, unless intolerance to any of the above is documented. Treatment for HF must be stable (including drug and dose) for 4 weeks prior to randomization, except diuretics (2 weeks stable) * Appropriate use of medical devices such as an implantable cardioverter defibrillator (ICD) or a cardiac resynchronization therapy (CRT) consistent with prevailing local or international guidelines, and if a device is required, it must have been implanted for at least 3 months prior to consent for CRT and 1 month prior to consent for ICD * Age ≥18 years and ≤80 years Exclusion Criteria: * Renal arterial anatomy that is ineligible for treatment * Myocardial infarction, unstable angina pectoris, or a cerebrovascular accident within 12 weeks prior to consent * Office systolic BP at screening \<90 mmHg * Clinically significant cardiac structural valvular disease, unless corrected by a properly functional prosthetic valve * Hypertrophic obstructive cardiomyopathy * Major surgery in the previous 12 weeks prior to consent * Hospitalization for decompensated CHF in the \<30 days prior to consent * Parenteral therapy for the treatment of CHF * Respiratory support (excluding sleep apnea therapy) * Left ventricular assist or planned heart transplantation * Patient is pregnant, nursing, or planning to be pregnant * Ineligibility to consent * Primary pulmonary hypertension (systolic PAP \>70 mmHg) * BMI ≥40 kg/m² * Any condition that would contraindicate the assessment of 6-min walk distance. * Patient has type I diabetes mellitus

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardio-renal syndrome are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Saarland University Medical Center, Department for Internal Medicine III

    Homburg/Saar, Saarland, 66421, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.